News

Filter

Current filters:

LyricaEli Lilly

151 to 160 of 97209 results

A top-20 pharma to utilize Xyntek-Antares serializing for China

A top-20 pharma to utilize Xyntek-Antares serializing for China

08-12-2014

A top 20 multi-national pharmaceutical research and manufacturer is utilizing the Xyntek-Antares solution…

ChinaPharmaceuticalProductionRegulationXyntek

Spanish government should consider linking pharmaceutical spending to GDP growth

Spanish government should consider linking pharmaceutical spending to GDP growth

08-12-2014

Pharmaceutical spending has fallen nearly 30% in Spain in last four years. According to IMS Health data,…

FinancialPharmaceuticalPoliticsPricingSpain

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

08-12-2014

Sandoz, the generics subsidiary of Swiss pharma major Novartis, has today released Phase III data that…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyResearchSandoz

Latest Ph III data for UCB’s brivaracetam presented at AES

Latest Ph III data for UCB’s brivaracetam presented at AES

08-12-2014

Positive primary efficacy and safety data from the latest Phase III study evaluating Belgian drugmaker…

BRIVARACETAMNeurologicalPharmaceuticalResearchUCB

Labeling update of Lundbeck and Otsuka’s Abilify Maintena approved by FDA

08-12-2014

The US Food and Drug Administration approved the labeling update of Abilify Maintena (aripiprazole) for…

Abilify MaintenaLundbeckNeurologicalOtsuka PharmaceuticalPharmaceuticalRegulationUSA

ASH 2014: Amgen and Onyx report primary endpoint met in Kyprolis combination trial

ASH 2014: Amgen and Onyx report primary endpoint met in Kyprolis combination trial

08-12-2014

USA-based Amgen and its subsidiary Onyx Pharmaceuticals announced the results of the Phase III ASPIRE…

AmgenBiotechnologyDexamethasoneKyprolisOncologyOnyx PharmaceuticalsResearchRevlimid

Sources say Merck to buy Cubist in $7 billion deal

Sources say Merck to buy Cubist in $7 billion deal

08-12-2014

Sources close to the matter say pharma giant Merck & Co has entered negotiations with Cubist Pharmaceuticals…

CubicinCubist PharmaceuticalsMerck & CoMergers & AcquisitionsPharmaceuticalUSA

ASH 2014: Merck reports overall response rate of 66% for its Keytruda in Hodgkin's lymphoma

ASH 2014: Merck reports overall response rate of 66% for its Keytruda in Hodgkin's lymphoma

08-12-2014

Keytruda (pembrolizumab), manufactured by pharma giant Merck & Co, has achieved an overall response rate…

KeytrudaMerck & CoOncologyPharmaceuticalResearchUSA

ASH 2014: AbbVie's venetoclax shows promise in Phase II trial

ASH 2014: AbbVie's venetoclax shows promise in Phase II trial

08-12-2014

US drugmaker AbbVie presented data at the American Society of Hematology’s annual meeting, demonstrating…

AbbVieOncologyPharmaceuticalResearchUSA

151 to 160 of 97209 results

Back to top